LIQUISOLID COMPACT OF MECLIZINE HYDROCHLORIDE: DEVELOPMENT AND OPTIMIZATION USING FACTORIAL DESIGN
DOI:
https://doi.org/10.22159/ijap.2025v17i2.53361Keywords:
Meclizine hydrochloride, Liquisolid compact, Factorial design, Motion sicknessAbstract
Objective: The study focuses on improving the dissolution rate of meclizine hydrochloride by developing a liquisolid compact.
Methods: Meclizine hydrochloride is used to prevent motion sickness but has slow dissolution, requiring it to be taken an hour before travel. Various water-miscible solvents were examined to determine the drug's solubility, with propylene glycol showing the highest solubility. Avicel® PH 102 was chosen as the carrier, and Aerosil® 200 as the coating material. The formulation was optimized using Design Expert software and 32 factorial design was used to study the effects of factors: carrier and coating ratio(X1) and drug concentration in liquid medication (%Cd)(X2) on responses: %cumulative drug release at 20 min (Y1) and angle of repose (Y2).
Results: The optimized formulation was selected using the software, with a carrier and coating ratio of 24.89 and drug concentration in liquid at 10.14% w/w. The optimized liquisolid tablet was evaluated for post-compression parameters and dissolution study. The drug was found to be non-crystalline based on Differential Scanning Calorimetry (DSC) and X-ray diffraction (XRD) studies, and the stability study showed no significant degradation.
Conclusion: The findings indicate that liquisolid formulation can be a promising alternative to achieve rapid onset of action and dissolution enhancement for poorly water-soluble drugs such as meclizine hydrochloride.
References
Darwesh AY, El Dahhan MS, Meshali MM. A new dual-function orodissolvable/dispersible meclizine HCl tablet to challenge patient inconvenience: in vitro evaluation and in vivo assessment in human volunteers. Drug Deliv Transl Res. 2021;11(5):2209-23. doi: 10.1007/s13346-020-00889-z, PMID 33443718.
Qazi F, Shoaib MH, Yousuf RI, Siddiqui F, Nasiri MI, Ahmed K. QBD based eudragit coated meclizine HCl immediate and extended-release multiparticulates: formulation characterization and pharmacokinetic evaluation using HPLC-Fluorescence detection method. Sci Rep. 2020;10(1):14765. doi: 10.1038/s41598-020-71751-y, PMID 32913337.
Vemula SK, Vangala M. Formulation development and characterization of meclizine hydrochloride sublimated fast dissolving tablets. Int Sch Res Not. 2014;2014:281376. doi: 10.1155/2014/281376, PMID 27355021.
Wang Z, Lee B, Pearce D, Qian S, Wang Y, Zhang Q. Meclizine metabolism and pharmacokinetics: formulation on its absorption. J Clin Pharmacol. 2012;52(9):1343-9. doi: 10.1177/0091270011414575, PMID 21903894.
George SJ, Vasudevan DT. Studies on the Preparation characterization and solubility of 2-HP-β-Cyclodextrin meclizine HCl inclusion complexes. J Young Pharm. 2012;4(4):220-7. doi: 10.4103/0975-1483.104365, PMID 23493156.
Meclizine. American society of Health-System Pharmacists; c 2024. Available from: https://medlineplus.gov/druginfo/meds/a682548.html. [Last accessed on 2 Jan 2025].
Jaydip B, Dhaval M, Soniwala MM, Chavda J. Formulation and optimization of liquisolid compact for enhancing dissolution properties of efavirenz by using DoE approach. Saudi Pharm J. 2020;28(6):737-45. doi: 10.1016/j.jsps.2020.04.016, PMID 32550806.
Spireas SS, Jarowski CI, Rohera BD. Powdered solution technology: principles and mechanism. Pharm Res. 1992;9(10):1351-8. doi: 10.1023/a:1015877905988, PMID 1448438.
Elkhodairy KA, Elsaghir HA, Al Subayiel AM. Formulation of indomethacin colon targeted delivery systems using polysaccharides as carriers by applying liquisolid technique. Bio Med Res Int. 2014;2014:704362. doi: 10.1155/2014/704362, PMID 24971345.
Baby JN, Manjila SB, Bijin EN, Constantine I, Pramod K, Valsalakumari J. Design and technology of liquisolid compacts. J App Pharm Sc. 2013;38 Suppl 1:S111-9. doi: 10.7324/JAPS.2013.38.S17.
Gajdziok J, Vranikova B. Enhancing of drug bioavailability using liquisolid system formulation. Ceska Slov Farm. 2015;64(3):55-66. doi: 10.36290/csf.2015.018, PMID 26400228.
LU M, Xing H, Jiang J, Chen X, Yang T, Wang D. Liquisolid technique and its applications in pharmaceutics. Asian J Pharm Sci. 2017;12(2):115-23. doi: 10.1016/j.ajps.2016.09.007, PMID 32104320.
Nagaich U. Pharmaceutical applications of liquisolid technique. J Adv Pharm Technol Res. 2018;9(2):43. doi: 10.4103/japtr.JAPTR_236_18, PMID 30131935.
Bhide P, Nachinolkar R. Formulation development and characterisation of meclizine hydrochloride fast dissolving tablets using solid dispersion technique. Int J App Pharm. 2018;10(4):141-6. doi: 10.22159/ijap.2018v10i4.26493.
Sisinthy SP, Selladurai S. Cinnarizine liquid solid compacts: preparation evaluation. Int J App Pharm. 2019;11(1):150-7. doi: 10.22159/ijap.2019v11i1.30109.
Pathak BK, Raghav M, Thakkar AR, Vyas BA, Shah PJ. Enhanced oral bioavailability of etodolac by the liquisolid compact technique: optimisation in vitro and in vivo evaluation. Curr Drug Deliv. 2021;18(4):471-86. doi: 10.2174/1567201817666201026111559, PMID 33106143.
Chella N, Shastri N, Tadikonda RR. Use of the liquisolid compact technique for improvement of the dissolution rate of valsartan. Acta Pharmaceutica Sinica B. 2012;2(5):502-8. doi: 10.1016/j.apsb.2012.07.005.
Rede SD, Jani RK. Solubility enhancement of paclitaxel by using biomaterial solubility enhancement of paclitaxel by using biomaterial. Res J Pharm Technol. 2022;15(11):5089-3.
Margret S, Blr M. Study of direct compression method for the preparation of quinapril hydrochloride tablets. Asian J Pharm Clin Res. 2020;13(1):202-11.
Spireas S, Bolton SM. Liquisolid systems and methods of preparing same. United States Patent US5800834A; 1996.
Hentzschel CM, Alnaief M, Smirnova I, Sakmann A, Leopold CS. Enhancement of griseofulvin release from liquisolid compacts. Eur J Pharm Biopharm. 2012;80(1):130-5. doi: 10.1016/j.ejpb.2011.08.001, PMID 21846502.
Panda S, Varaprasad R, Priyanka K, Swain RP. Liquisolid technique: a novel approach for dosage form design. Int J App Pharm. 2017;9(3):8-14. doi: 10.22159/ijap.2017v9i3.18698.
Patel DS, Pipaliya RM, Surti N. Liquisolid tablets for dissolution enhancement of a hypolipidemic drug. Indian J Pharm Sci. 2015;77(3):290-8. doi: 10.4103/0250-474x.159618, PMID 26180274.
Patric JS. Martins physical pharmacy and pharmaceutical sciences. 2nd ed. New Delhi: Wolters Kluwer (India) Pvt. Ltd; 2008.
Naureen F, Shah Y, Shah SI, Abbas M, Rehman IU, Muhammad S. Formulation development of mirtazapine liquisolid compacts: optimization using central composite design. Molecules. 2022;27(13):4005. doi: 10.3390/molecules27134005, PMID 35807252.
Gao Z, YU L, Clark S, Trehy M, Moore T, Westenberger B. Dissolution testing for bioavailability of over-the-counter (OTC) drugs a technical note. AAPS Pharm Sci Tech. 2015;16(5):1227-33. doi: 10.1208/s12249-015-0297-x, PMID 25680355.
Dalvadi H, Patel J, Shah D. Time and/or site-specific drug delivery of floating pulsatile release delivery system. Syst Rev Pharm. 2011;2(1):59-65. doi: 10.4103/0975-8453.83441.
Molaei MA, Osouli Bostanabad K, Adibkia K, Shokri J, Asnaashari S, Javadzadeh Y. Enhancement of ketoconazole dissolution rate by the liquisolid technique. Acta Pharm. 2018;68(3):325-36. doi: 10.2478/acph-2018-0025, PMID 31259692.
Jaydip B, Dhaval M, Soniwala MM, Chavda J. Formulation and optimization of liquisolid compact for enhancing dissolution properties of efavirenz by using DoE approach. Saudi Pharm J. 2020;28(6):737-45. doi: 10.1016/j.jsps.2020.04.016, PMID 32550806.
Cirri M, Mura P, Valleri M, Brunetti L. Development and characterization of liquisolid tablets based on mesoporous clays or silicas for improving glyburide dissolution. Pharmaceutics. 2020;12(6):503. doi: 10.3390/pharmaceutics12060503, PMID 32492869.
Dalal L, Allaf AW, El Zein H. Formulation and in vitro evaluation of self-nanoemulsifying liquisolid tablets of furosemide. Sci Rep. 2021;11(1):1315. doi: 10.1038/s41598-020-79940-5, PMID 33446749.
Sura RS, Subrahmanyam C, Rachamalla SS. Design and evaluation of liquisolid compacts of nebivolol hydrochloride. Int J App Pharm. 2022;14(2):293-307. doi: 10.22159/ijap.2022v14i2.43657.
Generally recognized as safe (GRAS). United States Food and Drug Administration; c2024. Available from: https://www.fda.gov/food/food-ingredients-packaging/generallyrecognizedsafe-gras. [Last accessed on 03 Jan 2025].
Ministry of health and family welfare. Indian pharmacopoeia. 1st ed. Ghaziabad: The Indian Pharmacopoeia Commission; 2022.
Vaskula S, Vemula SK, Bontha VK, Garrepally P. Liquisolid compacts: an approach to enhance the dissolution rate of nimesulide. J Appl Pharm Sci. 2012;2(5):115-21.
Nair HA, Gadhiraju G, Sunny G. Development of orodispersible tablets of loratadine containing an amorphous solid dispersion of the drug in soluplus® using design of experiments. Int J Pharm Pharm Sci. 2023;15(8):19-27. doi: 10.22159/ijpps.2023v15i8.47750.
Pai GK, Krishna V, Reddy S, Kishan YS, Aditya V, Bhanuprakash G. Physical evaluation of the uncoated tablets of glimepiride with different types of primary packaging. Res J Pharm Technol. 2012;5(3):404-7.
Oza N, Sahoo S, Sagar S. A 32 full factorial design for topical controlled releasetazarotene microsponge using HPMC gel. Int J App Pharm. 2019;11(5):12-8. doi: 10.22159/ijap.2019v11i5.34496.
Saeedi M, Akbari J, Morteza Semnani K, Enayati Fard R, Sar Reshteh Dar S, Soleymani A. Enhancement of dissolution rate of indomethacin: using liquisolid compacts. Iran J Pharm Res. 2011;10(1):25-34. PMID 24363677.
Bose A, Wong TW, Singh N. Formulation development and optimization of sustained release matrix tablet of itopride HCl by response surface methodology and its evaluation of release kinetics. Saudi Pharm J. 2013;21(2):201-13. doi: 10.1016/j.jsps.2012.03.006, PMID 23960836.
Published
How to Cite
Issue
Section
Copyright (c) 2025 TULARAM BAROT, KARUNA NAGULA, MOKSHA PATEL, L D PATEL
This work is licensed under a Creative Commons Attribution 4.0 International License.
